clopidogrel + metoprolol

**Clopidogrel + metoprolol** denotes concomitant cardiovascular treatment with the antiplatelet agent clopidogrel and the beta-1-selective adrenergic receptor blocker metoprolol. Clopidogrel is a prodrug whose active metabolite irreversibly inhibits platelet P2Y12 receptors, reducing ADP-mediated platelet activation and thrombosis. Metoprolol decreases heart rate, myocardial contractility, and cardiac oxygen demand through beta-1 adrenergic receptor antagonism. The combination has been evaluated as separate treatments in acute myocardial infarction studies, but the supplied name does not establish a unique, branded, or regulator-verified fixed-dose product. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00222573))

Other names

metoprolol + clopidogrel